Humanigen

Humanigen Shareholder Yield

Delisted

The Shareholder Yield of Humanigen (HGENQ) as of Oct 12, 2026 is 35.16 M %. In the previous year, Shareholder Yield was 156.57 M % — a change of -77.54% (lower).

Shareholder Yield

35.16 M %

YoY

-77.54%

Last updated:

Shareholder Yield of Humanigen is 2022 35.16 M % . Shareholder Yield of Humanigen was 2021 156.57 M % . It decreases by -77.54% lower compared to the previous year.

The Humanigen Shareholder Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Shareholder Yield
Date
Shareholder Yield
Jan 1, 2015
6.91 M USD
Jan 1, 2016
8.52 M USD
Jan 1, 2017
0.00 USD
Jan 1, 2018
2.34 M USD
Jan 1, 2019
428,571.43 USD
Jan 1, 2020
117.93 M USD
Jan 1, 2021
156.57 M USD
Jan 1, 2022
35.16 M USD
The Humanigen Shareholder Yield history
YEARShareholder YieldYoY
35.16 M %-77.54%
156.57 M %+32.76%
117.93 M %+27,417.65%
428,571.43 %-81.65%
2.34 M %—
0.00-100.00%
8.52 M %+23.36%
6.91 M %+11,642.86%
58,823.53 %—
Access this data via the Eulerpool API

Humanigen Stock analysis

What does Humanigen do? Humanigen Inc is a pharmaceutical company specializing in the discovery, development, and marketing of drugs, therapies, and solutions in the field of medical research. The company was originally founded in 2000 and is headquartered in Burlingame, California. One major focus of Humanigen Inc is the treatment of severe and life-threatening diseases such as cancer or HIV/AIDS that have not been sufficiently addressed by other medications. The company has developed a range of special technologies that enable it to develop innovative and effective therapies and drugs. An important aspect of Humanigen Inc's business model is collaboration with other companies, institutions, and research facilities worldwide. Through partnerships and cooperation, the company is able to cover the entire spectrum of research and development, allowing it to develop treatment options even faster and more effectively. Humanigen Inc has several different divisions and products designed for various applications. An important subsidiary of the company is the Humanigen Center for HIV Cure Research, which specifically focuses on combating HIV. There, the company works closely with scientists, researchers, and partners to develop new and innovative treatment options. Another important product of Humanigen Inc is the drug Lenzilumab. Lenzilumab is an antibody used to treat severe and life-threatening diseases such as cancer and COVID-19. Lenzilumab has shown great promise in clinical trials and could be the key to developing new and effective treatment options. In addition, Humanigen Inc has filed a variety of patents that enable it to develop new and innovative technologies in medical research. Many of these technologies are also licensed by other companies and research institutions, promoting the growth and expansion of Humanigen Inc. In recent years, the company has also placed a major focus on the field of digital technology. By utilizing big data, artificial intelligence, and other digital technologies, Humanigen Inc is able to develop new therapy options even faster and more effectively, catering specifically to the needs of patients and doctors. Overall, Humanigen Inc is an innovative and rapidly growing company focused on the development of new and effective treatment options for serious diseases. Through collaboration with other companies and institutions, the development of new technologies, and a targeted focus on the needs of patients and doctors, the company is able to respond even faster and more effectively to challenges in the field of medical research. Humanigen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humanigen stock

Shareholder Yield of Humanigen is 35.16 M % in 2022.

Shareholder Yield of Humanigen changed from 156.57 M % to 35.16 M %, representing a -77.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Shareholder Yield Humanigen since 2006 – with annual values, charts, and detailed analysis.

Shareholder yield combines dividend yield and buyback yield to show the total cash return to shareholders. It captures both dividends and share repurchases.

To evaluate Shareholder Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Shareholder Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Shareholder Yield's Humanigen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Humanigen

All Key Metrics — Humanigen